Clinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells.
Liquid biopsy of tumor through isolation of circulating tumor cells (CTCs) allows non-invasive, repetitive, and systemic sampling of disease. Although detecting and enumerating CTCs is of prognostic significance in metastatic cancer, it is conceivable that performing molecular and functional characterization on CTCs will reveal unprecedented insight into the pathogenic mechanisms driving lethal disease. Nanomaterial-embedded cancer diagnostic platforms, i.e., NanoVelcro CTC Assays represent a unique rare-cell sorting method that enables detection isolation, and characterization of CTCs in peripheral blood, providing an opportunity to noninvasively monitor disease progression in individual cancer patients. Over the past decade, a series of NanoVelcro CTC Assays has been demonstrated for exploring the full potential of CTCs as a clinical biomarker, including CTC enumeration, phenotyping, genotyping and expression profiling. In this review article, the authors will briefly introduce the development of three generations of NanoVelcro CTC Assays, and highlight the clinical applications of each generation for various types of solid cancers, including prostate cancer, pancreatic cancer, lung cancer, and melanoma.
['Chen|Jie-Fu|JF|', 'Zhu|Yazhen|Y|', 'Lu|Yi-Tsung|YT|', 'Hodara|Elisabeth|E|', 'Hou|Shuang|S|', 'Agopian|Vatche G|VG|', 'Tomlinson|James S|JS|', 'Posadas|Edwin M|EM|', 'Tseng|Hsian-Rong|HR|']
D000818:Animals D002469:Cell Separation D003955:Diagnostic Tests, Routine D006801:Humans D050997:Nanomedicine D009369:Neoplasms D009360:Neoplastic Cells, Circulating
Circulating tumor cell